Terms of the accord weren’t fully disclosed in a filing yesterday in federal court in Newark, New Jersey, referring to a license agreement dated Aug. 16 between the two companies. Pfizer sued Impax in 2008, claiming it infringed three patents in applying for U.S. Food and Drug Administration approval to copy its extended-release capsules.
The settlement bars Impax from selling any generic version of the drug during the life of two of the patents “except as permitted under the settlement and license agreement” between the companies.
Detrol and Detrol LA generated $883 million in global sales last year for Pfizer, including $557 million in the U.S.
“Pfizer confirms that it has settled its patent infringement lawsuit against Impax Labs involving Pfizer’s patents covering Detrol LA,” Christopher Loder, a spokesman for New York-based Pfizer, said in an e-mail. “The terms of this agreement are confidential.”
Mark Donohue, a spokesman for Hayward, California-based Impax, couldn’t immediately be reached for comment.
The case is Pfizer Inc. v. Impax Laboratories, 2:08- cv-02137, U.S. District Court, District of New Jersey (Newark).
To contact the reporters on this story: David Voreacos in Newark, New Jersey, at firstname.lastname@example.org; Susan Decker in Washington at email@example.com.
To contact the editors responsible for this story: Michael Hytha at firstname.lastname@example.org; Bernard Kohn at email@example.com.